Compounds > apovincaminic acid
Page last updated: 2024-11-07

apovincaminic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

apovincaminic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160154
CHEMBL ID252560
SCHEMBL ID1171662
MeSH IDM0102253

Synonyms (25)

Synonym
27773-65-5
apovincaminic acid
(3s,16s)cis-apovincaminic acid
cis-apovincaminic acid
CHEMBL252560
einecs 248-651-1
(3alpha,16alpha)-eburnamenine-14-carboxylic acid
zd6zf4c86q ,
unii-zd6zf4c86q
(+)-cis-apovincaminic acid
apovincamin-22-oic acid
(+)-apovincaminic acid
SCHEMBL1171662
ZFCQLDAGNBFMJQ-QUCCMNQESA-N
1h-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylic acid, 13a-ethyl-2,3,5,6,13a,13b-hexahydro-, (13as,13bs)-
(15s,19s)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylic acid
(13.alpha.s,13.beta.s)-13.alpha.-ethyl-2,3,5,6,13.alpha.,13.beta.-hexahydro-1h-indolo(3,2,1-de)pyrido(3,2,1-ij)(1,5)naphthyridine-12-carboxylic acid
1h-indolo(3,2,1-de)pyrido(3,2,1-ij)(1,5)naphthyridine-12-carboxylic acid, 13.alpha.-ethyl-2,3,5,6,13.alpha.,13.beta.-hexahydro-, (13.alpha.s,13.beta.s)-
apovincamine, derivative of
(3.alpha.,16.alpha.)-eburnamenine-14-carboxylic acid
eburnamenine-14-carboxylic acid, (3.alpha.,16.alpha.)-
DTXSID80950458
eburnamenine-14-carboxylic acid
apovincamin-22-oic acid hydrochloride salt
1ST10916

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic curves of both vinpocetine and AVA have been determined prior to the chronic administration and on the last day of the treatment, whereas between the 2nd and 6th days, concentration was measured once daily."( Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.
Kozma, K; Miskolczi, P; Polgár, M; Vereczkey, L, )		0.38
" The apparent pharmacokinetic constants were determined."( Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter.
Bodiu, B; Leucuta, SE; Vlase, L, 2005)		0.53

Bioavailability

ExcerptReferenceRelevance
" The relative bioavailability of the test (generic) product (Vimpocetina) with respect to the reference product was determined in a single dose, randomized, crossover study."( Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter.
Bodiu, B; Leucuta, SE; Vlase, L, 2005)		0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID697755Octanol-water partition coefficient, log P of anionic form of compound at 0.15 M ionic strength by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
AID312791Protective effect against diazepam-induced learning-deficit in Wistar rat at 5 mg/kg, po by water labyrinth test2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Synthesis and evaluation of 2'-hydroxyethyl trans-apovincaminate derivatives as antioxidant and cognitive enhancer agents.
AID697756Octanol-water partition coefficient, log P of zwitter ionic form of compound at 0.15 M ionic strength by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
AID697754Octanol-water partition coefficient, log P of cationic form of compound at 0.15 M ionic strength by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
AID697757Octanol-water partition coefficient, log P of noncharged form of compound at 0.15 M ionic strength by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
AID697759Octanol-water distribution coefficient, log D of the compound at pH 5.4 by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
AID697758Octanol-water distribution coefficient, log D of the compound at pH 0.82 by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
AID697761Octanol-water distribution coefficient, log D of the compound at pH 13.18 by stir flask method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Zwitterions can be predominant in membrane penetration of drugs: experimental proof.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.00)18.7374
1990's8 (32.00)18.2507
2000's7 (28.00)29.6817
2010's5 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.14 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.45%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (90.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		2.1102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
glycine
[no description available]		2.110alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.3920alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
1-propanol
1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.. propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.		1.9710propan-1-ols;
short-chain primary fatty alcohol		metabolite;
protic solvent
tocopheroxy radical
tocopheroxy radical: RN given refers to radical ion (1+), (2R-(2R*(4R*,8R*)))-isomer; RN for cpd without isomeric designation not available 12/90		2.0410tocopherol
idebenone
[no description available]		2.04101,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		1.9810methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
vincamine
Vincamine: A major alkaloid of Vinca minor L., Apocynaceae. It has been used therapeutically as a vasodilator and antihypertensive agent, particularly in cerebrovascular disorders.		2.4120alkaloid ester;
hemiaminal;
methyl ester;
organic heteropentacyclic compound;
vinca alkaloid		antihypertensive agent;
metabolite;
vasodilator agent
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		2.0510amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
butylated hydroxytoluene
2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.		2.0410phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.110glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
vinpocetine
vinpocetine: whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation		5.74201alkaloidgeroprotector
quercetin
[no description available]		2.04107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
aluminum hydroxide, magnesium hydroxide, drug combination
aluminum hydroxide, magnesium hydroxide, simethicone drug combination: antacid contains aluminum hydroxide, magnesium hydroxide and simethicone; mylanta II contains aluminum/magnesium hydroxide mixture		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.1710
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4420
Lactic Acidosis
[description not available]		02.110
Cerebral Ischemia
[description not available]		02.4420
Injury, Ischemia-Reperfusion
[description not available]		02.110
Acidosis, Lactic
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as DIABETES MELLITUS; LEUKEMIA; or LIVER FAILURE.		02.110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.4420
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4320
Apoplexy
[description not available]		02.0110
Anterior Circulation Transient Ischemic Attack
[description not available]		02.0110
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		02.0110
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		07.0110
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9610
Brain Vascular Disorders
[description not available]		01.9610
Cerebrovascular Disorders
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.		01.9610
Brain Embolism and Thrombosis
[description not available]		03.3611
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9710